Advertisement
Advertisement
U.S. markets open in 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Dermata Therapeutics, Inc. (DRMA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5400+0.0195 (+3.75%)
At close: 04:00PM EDT
0.5400 0.00 (0.00%)
Pre-Market: 08:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close0.5205
Open0.5100
Bid0.5100 x 3100
Ask0.5800 x 900
Day's Range0.4403 - 0.5486
52 Week Range0.4350 - 6.9500
Volume607,340
Avg. Volume1,573,328
Market Cap5.455M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.8510
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dermata Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
  • ACCESSWIRE

    Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

  • ACCESSWIRE

    Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

    / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022.

  • ACCESSWIRE

    Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

    / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress and reported financial results for the quarter ended June 30, 2022.

Advertisement
Advertisement